Use of probiotics as an adjuvant To sequential H. pylori eradication therapy: Impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance

Turkish Journal of Gastroenterology

Volumn 28, Issue 1, 2017, Pages 3-11

  Çekin, Ayhan Hilmi ^a   Şahintürk, Yasin ^a   Harmandar, Ferda Akbay ^a   Uyar, Seyit ^a   Yolcular, Başak Oǧuz ^b   Çekin, Yeşim ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Eradication; H. Pylori; Patient compliance; Probiotics; Sequential therapy; Side effects

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; PANTOPRAZOLE; PLACEBO; PROBIOTIC AGENT; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ADJUVANT THERAPY; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BIFIDOBACTERIUM ANIMALIS; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RASH; TREATMENT DURATION; TREATMENT OUTCOME; ABDOMINAL PAIN; ANOREXIA; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DIZZINESS; DRUG EFFECTS; DRUG ERUPTIONS; DRUG RESISTANCE; HEADACHE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MEDICATION COMPLIANCE; MIDDLE AGED; NAUSEA; NUMBERS NEEDED TO TREAT; SYMPTOM ASSESSMENT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ABDOMINAL PAIN; ADULT; AMOXICILLIN; ANOREXIA; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM ANIMALIS; CLARITHROMYCIN; DIARRHEA; DIZZINESS; DRUG ERUPTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HEADACHE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; NAUSEA; NUMBERS NEEDED TO TREAT; PROBIOTICS; PROTON PUMP INHIBITORS; SYMPTOM ASSESSMENT; TREATMENT OUTCOME;

EID: 85014469197     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: 10.5152/tjg.2016.0278     Document Type: Article

References (57)

1. Go MF. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther 2002;16(Suppl 1):3-15.
2. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-86.
3. Vergara M, Vallve M, Gisbert JP, Calvet X. Meta-analysis: comparative efficacy of different proton-pump inhibitors in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:647-54.
4. Malfertheiner P, Meqraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Masstricht IV/Florence Consensus Report. Gut 2012;61:646-64.
5. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology: American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
6. Meqraud F. Basis of the management of drug-resistant Helicobacter pylori infection. Drugs 2004;64:1893-904.
7. Yoqueswaran K, Chen G, Cohen L, et al. How well is Helicobacter pylori treated in usual practice? Can J Gastroenterol 2011;25:543-6.
8. Zagari RM, Bianchi-Porro G, Fiocca R, Gasbarrini G, Roda E, Bazzoli F. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56:475-9.
9. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-5.
10. Ermis F, Senocak Tasci E. Current Helicobacter pylori treatment in 2014. World J Methodol 2015;5:101-7.
11. Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol 2012;5:151-7.
12. McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of Helicobacter pylori. Helicobacter 2004;9:42-8.
13. Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40:683-7.
14. Bell GD, Powell K, Burridge SM, et al. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the im-portance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992;6:427-35.
15. FAO/WHO. Report on Joint FAO/WHO Expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, FAO/WHO, 2001.
16. Lionetii E, Indrio F, Pavone L, Borrelli G, Cavallo L, Francavilla R. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter 2010;15:79-87.
17. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS One 2014;9:e111030.
18. Gong Y, Li Y, Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015;8:6530-43.
19. Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: A meta-analysis. Exp Ther Med 2015;9:707-16.
20. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
21. Hamilton-Miller JM. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int J Antimicrob Agents 2003;22:360-6.
22. Tursi A, Brandimarte G, Giorgetti GM, Modeo ME. Effect of Lactobacillus casei supplementation on the effectiveness and tolerability of a new second-line 10-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection. Med Sci Monit 2004;10:CR662-6.
23. Ozdil K, Calhan T, Sahin A, et al. Levofloxacin based sequential and triple therapy compared with standard plus probiotic combination for Helicobacter pylori eradication. Hepatogastroenterology 2011;58:1148-52.
24. Huebner ES, Surawicz CM. Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am 2006;35:355-65.
25. Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007;25:155-68.
26. Zou J, Dong J, Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter 2009;14:449-59.
27. Sachdeva A, Naqpal J. Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and metaanalysis of randomized-controlled trials. Eur J Gastroenterol Hepatol 2009;21:45-53.
28. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 2010;32:1069-79.
29. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containning probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:25-32.
30. Zheng X, Lyu L, Mei Z. Lactobacillus-containingprobiotic supplementation increases Helicobacter plyori eradication rate: evidence from a metaanalysis. Rev Esp Enferm Dig 2013;105:445-53.
31. Yoon H, Kim N, Kim JY, et al. Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection. J Gastroenterol Hepatol 2011;26:44-8.
32. Scaccianoce G, Zullo A, Hassan C, et al. Triple therapies plus different probiotics for Helicobacter pylori eradication. Eur Rev Med Pharmacol Sci 2008;12:251-6.
33. Ahmad K, Fatemeh F, Mehri N, Maryam S. Probiotics for the treatment of pediatric Helicobacter pylori infection: a randomized double blind clinical trial. Iran J Pediatr 2013;23:79-84.
34. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol 2002;97:2744-9.
35. Shavakhi A, Tabesh E, Yaghoutkar A, et al. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-controlled triple-blind study. Helicobacter 2013;18:280-4.
36. Navarro-Rodriguez T, Silva FM, Barbuti RC, et al. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study. BMC Gastroenterol 2013;13:56.
37. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-86.
38. Zhang MM, Qian W, Qin YY, He J, Zhou YH. Probiotics in Helicobacter pylori eradication therapy: a systematic review and metaanalysis. World J Gastroenterol 2015;21:4345-57.
39. Kim MN, Kim N, Lee SH, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-8.
40. Armuzzi A, Cremonini F, Bartolozzi F, et al. The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2001;15:163-9.
41. Faul F, Erdfelder E, Lang AG, Buchner A. G∗Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-91.
42. Nadir I, Yonem O, Ozin Y, Kilic ZM, Sezgin O. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J 2011;104:102-5.
43. Sheu BS, Wu JJ, Lo CY, et al. Impact of supplement with Lactobacillusand Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:1669-75.
44. Gispert JP, Khorrami S, Calvet X, Gabriel R, Carballo F, Pajares JM. Meta-analysis: Proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;18:757-66.
45. Dai C, Zheng CQ, Jiang M. Efficacy of probiotics in Helicobacter pylori eradication therapy. J Clin Gastroenterol 2013;47:814-5.
46. Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy - a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther 2005;21:1263-72.
47. Hauser G, Salkic N, Vukelic K, JajacKnez A, Stimac D. Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial. Medicine (Baltimore) 2015;94:e685.
48. Adamsson I, Nord CE, Lundquist P, Sjostedt S, Edlund C. Comparative effects of omeprazole, amoxycillin, plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal micrōora in Helicobacter pylori-infected patients. J Antimicrob Chemother 1999;44:629-40.
49. Tomomasa T, Kuroume T, Arai H, Wakasashi K, Itoh Z. Erythromicin induces migrating motor complexes in human gastrointestinal tract. Dig Dis Sci 1986;31:157-61.
50. Bortolotti M, Brunelli F, Sarti P, Mari C, Miglioli M. Effects of oral clarithromycin and amoxicillin on interdigestive gastrointestinal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. Aliment Pharmacol Ther 1998;12:1021-5.
51. Isolauri E, Kirjavainen PV, Salminen S. Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 2002;50(Suppl 3):III54-9.
52. Buhling A, Radun D, Muller WA, Malfertheiner P. Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora. Aliment Pharmacol Ther 2001;15:1445-52.
53. de Boer WA, Tytgat GNJ. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995;30:401-7.
54. Franceschi F, Cazzato A, Nista EC, et al. Role of probiotics in patients with Helicobacter pylori infection. Helicobacter 2007;12(Suppl 2):59-63.
55. der Merwe S, Vaz Coelho LG, Fock M, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011;20:299-304.
56. Penston JG, McColl KE. Eradication of Helicobacter pylori: an objective assessment of current therapies. Br J Clin Pharmacol 1997;43:223-43.
57. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection in clinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy. Helicobacter 2012;17:254-63.